1. Therapeutic promise of the targets and proposed

mechanisms of action just presented? 

Other promising approaches not presented?  

2. From a clinical perspective, where is the unmet need in DME and wet AMD?  Neuroprotection, anti-fibrosis, anti-permeability,

anti-angiogenesis, other?

3. As these and other phase 2/3 trials approach proof of concept, what will represent a clinically meaningful visual improvement above and beyond anti-VEGF-A therapy?  A mean improvement

of 4-5 letters?  Injection burden?  Other?

4. Assuming approval of one or more of the discussed drugs as add-on or adjunctive therapy,

how will this impact patient flow and injection practices? 

What will retina practices look like in 2020?